NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 38,236 shares, a decrease of 91.8% from the August 31st total of 469,120 shares. Currently, 2.8% of the shares of the company are short sold. Based on an average daily volume of 40,192 shares, the days-to-cover ratio is currently 1.0 days.

NeuroSense Therapeutics Price Performance

Shares of NRSN traded down $0.22 during trading hours on Friday, hitting $7.18. The stock had a trading volume of 955 shares, compared to its average volume of 12,289. NeuroSense Therapeutics has a 12 month low of $5.00 and a 12 month high of $26.64. The firm has a market capitalization of $13.64 million, a PE ratio of -0.66 and a beta of 1.60. The stock has a fifty day moving average price of $9.06 and a 200 day moving average price of $13.20.

Institutional Investors Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new position in NeuroSense Therapeutics stock. Yorkville Advisors Global LP acquired a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned 0.21% of NeuroSense Therapeutics as of its most recent SEC filing. 1.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on NRSN shares. Weiss Ratings downgraded NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. HC Wainwright assumed coverage on shares of NeuroSense Therapeutics in a research note on Thursday, September 3rd. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NeuroSense Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $170.00.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.

NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS.